Harmony Biosciences Financial Statements
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Harmony Biosciences revenue and earnings
In fiscal 2025, Harmony Biosciences generated $868.5 million in revenue, up 21.5% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $158.7 million (+9.1% year over year), for a net margin of 18.3% versus a median of 20.4% in the prior 5 years. Gross margin was 77.2% (down from 78.1%) and operating margin 24.0%.
Diluted earnings per share came in at $2.71, up from $2.51. Over the last 5 fiscal years, HRMY's revenue has grown at a 40.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Harmony Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 868.45M | 714.73M | 582.02M | 437.86M | 305.44M | 159.74M | 6.00M |
| Revenue growth (YoY) | +21.51% | +22.80% | +32.93% | +43.35% | +91.21% | +2564.59% | — |
| Cost of Revenue | 198.34M | 156.81M | 121.24M | 83.48M | 55.52M | 27.74M | 1.58M |
| Gross Profit | 670.11M | 557.92M | 460.79M | 354.37M | 249.92M | 132.00M | 4.42M |
| Operating Expenses | 461.64M | 367.09M | 268.76M | 234.19M | 162.39M | 115.02M | 150.32M |
| Research & Development | 189.59M | 145.82M | 76.06M | 70.89M | 30.37M | 19.45M | 69.59M |
| Selling, General & Admin | 272.05M | 221.27M | 192.69M | 163.30M | 132.03M | 95.57M | 80.73M |
| Operating Income | 208.47M | 190.83M | 192.03M | 120.19M | 87.53M | 16.99M | -145.90M |
| Interest Expense | 14.65M | 17.50M | 23.76M | 18.80M | 24.19M | 28.61M | 7.36M |
| Other Income (Expense) | -680.00K | -68.00K | 159.00K | 169.00K | 16.00K | -3.07M | — |
| Pretax Income | 215.06M | 191.80M | 173.40M | 104.69M | 37.43M | -36.94M | -151.98M |
| Income Tax | 56.38M | 46.31M | 44.54M | -76.78M | 2.83M | — | — |
| Net Income | 158.69M | 145.49M | 128.85M | 181.47M | 34.60M | -36.94M | -151.98M |
| Net Income growth (YoY) | +9.07% | +12.91% | -28.99% | +424.52% | — | — | — |
| EPS (Basic) | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 | -2.48 | -24.07 |
| EPS (Diluted) | 2.71 | 2.51 | 2.13 | 2.97 | 0.58 | -2.48 | -24.07 |
| Shares Outstanding (Basic) | 57.49M | 56.89M | 59.47M | 59.17M | 57.53M | 25.77M | 7.78M |
| Shares Outstanding (Diluted) | 58.54M | 57.87M | 60.37M | 61.10M | 59.21M | 25.77M | 7.78M |
| EBITDA | — | 191.09M | 192.54M | 120.61M | 87.94M | 17.38M | -145.51M |
| Gross Margin | 77.16% | 78.06% | 79.17% | 80.93% | 81.82% | 82.64% | 73.69% |
| Operating Margin | 24.00% | 26.70% | 32.99% | 27.45% | 28.66% | 10.63% | -2433.76% |
| Net Margin | 18.27% | 20.36% | 22.14% | 41.44% | 11.33% | -23.13% | -2535.06% |
This table shows 7 annual periods of Harmony Biosciences's income statement, from FY 2025 back to FY 2019, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow HRMY's reporting calendar. What is a income statement?